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Abstract
Objective: Best long-term practice in primary HIV-1 infection (PHI) remains
unknown for the individual. A risk-based scoring system associated with surrogate
markers of HIV-1 disease progression could be helpful to stratify patients with PHI
at highest risk for HIV-1 disease progression.
Methods: We prospectively enrolled 290 individuals with well-documented PHI in
the Zurich Primary HIV-1 Infection Study, an open-label, non-randomized,
observational, single-center study. Patients could choose to undergo early
antiretroviral treatment (eART) and stop it after one year of undetectable viremia, to
go on with treatment indefinitely, or to defer treatment. For each patient we
calculated an a priori defined ‘‘Acute Retroviral Syndrome Severity Score’’
(ARSSS), consisting of clinical and basic laboratory variables, ranging from zero to
ten points. We used linear regression models to assess the association between
ARSSS and log baseline viral load (VL), baseline CD4+ cell count, and log viral
setpoint (sVL) (i.e. VL measured $90 days after infection or treatment interruption).
Results: Mean ARSSS was 2.89. CD4+ cell count at baseline was negatively
correlated with ARSSS (p50.03, n5289), whereas HIV-RNA levels at baseline
showed a strong positive correlation with ARSSS (p,0.001, n5290). In the
regression models, a 1-point increase in the score corresponded to a 0.10 log
increase in baseline VL and a CD4+cell count decline of 12/ml, respectively. In
patients with PHI and not undergoing eART, higher ARSSS were significantly
associated with higher sVL (p50.029, n564). In contrast, in patients undergoing
eART with subsequent structured treatment interruption, no correlation was found
between sVL and ARSSS (p50.28, n540).
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Conclusion: The ARSSS is a simple clinical score that correlates with the best-
validated surrogate markers of HIV-1 disease progression. In regions where ART is
not universally available and eART is not standard this score may help identifying
patients who will profit the most from early antiretroviral therapy.
Introduction
Since 2010, HIV treatment guidelines recommend early antiretroviral therapy
(eART) in case of symptomatic primary HIV-infection (PHI) [1], fostered by
increasing evidence that immediate treatment is beneficial for patients with PHI
[2–6]. On an individual level, however, best long-term practice in PHI remains
uncertain and the value of eART is still debated due to controversial results
reported in literature [2–4, 6–9]. Several studies report a relationship between the
severity of PHI and disease progression and death [10–12]. Based on these data it
is convincing that patients with severe manifestation of PHI probably benefit the
most from prompt initiation of ART. On the other hand, there exist no clear
definition of severe PHI and withholding ART to study the natural history of the
HIV-infection has been unethical for almost two decades. We therefore developed
the Acute Retroviral Syndrome Severity Score (ARSSS), which includes clinical
symptoms and a few general laboratory parameters that are regularly obtained in a
routine primary care setting for patients presenting with PHI. We hypothesized
that the intensity of the clinical presentation of PHI expressed by our newly
developed ARSSS correlates with the best validated surrogate markers associated
with HIV-1 disease progression [11, 13, 14]. Our aim was to create an easy
obtainable risk score which could help clinicians to identify patients who might
profit most of eART, in particularly in regions where universal ART is not
available. We evaluated our ARSSS in 290 individuals with a well-documented
PHI within the frame of the Zurich Primary HIV-infection study.
Study Design, Patients and Methods
Study design and patient selection
Between January 2002 and September 2012 we prospectively enrolled 290
individuals with a documented PHI in the longitudinal Zurich Primary HIV
Infection Study (ZPHIS), which is an open-label, non-randomized, observational,
single-center study (http://clinicaltrials.gov, ID 5 NCT00537966) [5, 6, 15]. All
patients $18 years who fulfilled the inclusion criteria of a documented acute or
recent HIV infection (definition see below) and who gave their informed consent
were included in the study. Patients could choose to undergo eART and stop it
after one year of undetectable viremia (,50 copies HIV-1 RNA/ml plasma), to go
on with treatment indefinitely, or to defer treatment. During the first visit, a
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detailed history of symptoms and signs of the acute retroviral syndrome (ARS)
was obtained, as well as a physical examination and standard laboratory
parameters (including full blood count and chemistry in addition to specific HIV-
1 laboratory parameters such as HIV-1 viral load, CD4+ cell count, HIV-1
Immunoblot, p24 antigen and genotypic resistance testing). Patients were actively
screened for acute hepatitis B and C, syphilis, gonorrhea, chlamydia trachomatis
and herpes simplex. If the patient was referred from an external physician, data
from the first external visit were recorded.
Ethics Statement
The ethic committee of the University Hospital Zurich approved the study
protocol and a written informed consent was obtained from all patients.
Definition of acute and recent primary HIV-infection and of
estimated date of infection
Acute/recent PHI was confirmed in all patients as previously published [6, 15, 16]:
acute HIV-infection was defined as ARS and negative or indeterminate
Westernblot in the presence of a positive p24-antigen and/or detectable HIV-1
RNA; or as a documented seroconversion with a 4th generation HIV screening test
with or without symptoms during the past 90 days. Recent infection was defined
as possible ARS, positive Westernblot and detectable HIV-RNA and a negative
HIV-gp120 avidity or detuned assay; or as a documented acute HIV-1 infection
with referral to our center more than 90 days after presumed date of infection. For
each patient an estimated date of infection (EDI) was determined as previously
described [5, 6, 15] by taking into account the pattern of different assay reactivity’s
(first positive and last negative HIV test, negative, indeterminate and positive WB,
positive p24 antigen, and avidity assay), patient’s reports of unambiguous risk
contacts, and timing of onset of ARS symptoms.
Antiretroviral treatment and follow-up
Since the beginning of the study in 2002, eART was offered to all patients in a
research setting, even though general treatment guidelines did not yet recommend
eART for PHI patients [17]. Over time these treatment recommendations have
changed towards treating HIV-infected individuals regardless of their CD4+ cell
count, including patients with PHI [1, 18]. The initial treatment consisted of a
ritonavir-boosted protease inhibitor (PI) combined with two nucleoside reverse
transcriptase inhibitors (nRTI) (e.g. lopinavir/ritonavir or darunavir/ritonavir in
combination with zidovudine/lamivudine or emtricitabine/tenofovir) reflecting
the introduction of these drugs into clinical practice [1, 17, 18]. Treatment was
continued for at least 12 months when plasma HIV- RNA was ,50 copies/ml.
After one year of suppressed viremia, patients could choose to stop ART. Of note,
structured treatment interruption was no longer recommended since 2010 due to
increasing evidence that effect of eART after treatment stop is only transient and
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vanishes over the time [19] and due to a change in treatment recommendations
towards universal treatment [1]. In the case of structured treatment interruption,
reintroduction of cART was recommended to the patients if CD4+ cell count
dropped to below 350 copies/ml [1, 20]. After cessation of cART, the VL and
CD4+ cell counts were collected every 2-4 weeks during the first three months and
then on every regular visit four times annually.
Acute retroviral syndrome
Based on an extensive literature search we defined 17 symptoms and signs which
we considered ARS symptoms and signs (Table 1) [21–31]. An ARS was stated in
the presence of fever plus at least one of the 17 symptoms/signs or, in absence of
fever, $2 symptoms/signs.
Acute Retroviral Syndrome Severity Score
We intended to develop an ARSSS which could be calculated easily within a short
time without including time-consuming, expensive, or difficult to perform
laboratory analysis (Table 2). The ARSSS was defined a priori. We intentionally
did not perform separate analyses of individual variables. The six variables and
their weight were chosen based on epidemiological and clinical evidence and our
own profound experience with PHI. For each patient we calculated an ARSSS
ranging from zero to 10 points. The rational for using the six scoring variables was
based on following considerations and evidence: (i) Severe neurological
symptoms, inpatient treatment, fever and age .50 years: it has been shown that
patients with prolonged or symptomatic manifestation of primary HIV infection
and older HIV patients have an increased risk of HIV-1 disease progression [10–
12, 32, 33]. Of note, a recent publication showed that encephalitis and meningitis
are a surrogate for severe PHI and predict faster disease progression [11]. (ii) Low
platelet count and elevated aminotransferases: these laboratory markers have been
demonstrated to predict faster disease progression in patients with primary and
chronic HIV-infection [11, 34–36].
Baseline CD4+ cell count, baseline viral load and viral setpoint.
Baseline VL and baseline CD4+ cell count were defined as the first values available.
The viral setpoint (sVL) was defined as the first HIV-RNA measurement$90 days
after the EDI in treatment-nai¨ve patients and $90 days after controlled treatment
interruption in patients with eART [6]. The cutoff point of$90 days after the EDI
was chosen based on the observation that the initially very high levels of viral
HIV-1 RNA and DNA, which are a hallmark of acute HIV-1 infection, appear to
level off after approximately 3 months post-infection [6].
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Genome-wide association analysis
Genomic DNA samples were genotyped using the HumanOmniExpress chip
(Illumina), which features .700,000 single nucleotide polymorphisms (SNPs).
SNPs were filtered based on missingness (dropped if called in ,98% of
participants), minor allele frequency (dropped if ,1%) and severe deviation from
Hardy–Weinberg equilibrium (dropped if p,106). High-resolution HLA class I
typing was imputed from the SNP data [37]. We used linear regression to test for
association between genetic variants and ARSSS. To avoid spurious associations
resulting from population stratification, we used a modified Eigenstrat method,
which derives the principal components of the correlations among SNPs [38]:
population outliers were discarded, and the coordinates of the significant
Table 1. Symptoms of acute retroviral syndrome reported in eleven retrospective studies or review articles.
Symptoms/signs of ARS Median % Range %
Fever 78 23–100
Skin rash 38 4–75
Pharyngitis 48 2–95
Lymphadenopathy 44 7–75
Myalgia 46 14–92
Headache 44 18–58
Diarrhea 32 14–48
Arthralgias 27 5–72
Cough 25 4–45
Nausea 32 6–67
Malaise/fatigue 64 12–92
Vomiting 32 3–67
Weight loss 21 2–46
Genital ulcer 3 3–10
Oral ulcers 17 9–30
Aseptic Meningitis 12 0–24
Night sweat 14 9–48
doi:10.1371/journal.pone.0114111.t001
Table 2. Acute Retroviral Syndrome Severity Score (ARSSS).
Parameters Related scoring point(s)
Severe neurological symptomsa 3
Inpatient treatment 3
Age $50 years 1
Fever (self-reported or documented $38˚ degrees Celsius) 1
Elevated liver enzymes (ASAT and/or ALAT $30 U/l) 1
Thrombocytopenia (platelet count ,150 G/l) 1
Maximum value 10
ae.g. encephalitis, aseptic meningitis, paresis, facial nerve paresis
doi:10.1371/journal.pone.0114111.t002
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principal component axes were included in the association tests to correct for
residual stratification. Bonferroni’s correction was applied for multiple testing.
Statistical analysis
We used linear regression models to assess the impact of ARSSS on log10 VL.
Since the baseline VL was strongly associated with the time-point of measurement
(i.e. days after EDI), we corrected for the timepoint of VL measurement in a
multivariable regression model. This model included both the ARSSS and the time
between the viral load measurement and the EDI as explanatory variables.
Specifically, we included time both as a linear and as quadratic term in order to
capture the non-monotonic changes of virus load over time. The impact of ARSSS
on treatment initiation was assessed using Cox-proportional hazard models (with
event 5 ‘‘treatment initiation’’) and logistic regression (with outcome 5‘‘patient
started treatment within a given time-window’’).
Results
Patient characteristics
We analysed 290 individuals with a documented PHI, including 271 males. Self-
reported transmission modes included men who have sex with men (MSM)
(78%), heterosexual (20%), intravenous drug abuse (IVDA) (1%) and others
(1%). The most prevalent HIV-subtype was B (76%), followed by CRF01_AE
(7%), A (4%) and C (2%). 23 patients (8%) showed $ one mutation associated
with transmitted drug resistance (TDR). Of all individuals, 17% presented with
signs of a concomitant STI at presentation. 141 patients (49%) first consulted
their primary physician, 69 (24%) the hospital and 42 (14%) an outpatient unit
(Table 3).
Acute primary HIV infection and estimated date of infection
PHI was classified in 242 (83%) individuals as ‘‘acute’’ and in 48 (17%) as
‘‘recent’’ infection. Of the acutely and recently infected patients, 226 of 242 (93%)
and 31 of 48 (65%) individuals presented with an ARS, respectively. Of all 290
patients, 16 patients (6%) presented without any symptoms and were diagnosed
by routine HIV testing. Seventeen patients (6%) presented with symptoms and
signs not considered as ARS. Patients were also classified according to the widely
used Fiebig stages (Table 2), which are based on the sequential detectability of a
number of direct and indirect HIV-1 diagnostic tests (e.g. plasma HIV-1 RNA,
p24antigen, HIV-1-specific antibodies detected by ELISA and by western blot)
[39]. The mean time between the EDI and the first positive HIV-test overall was
43 days (range 4 to 180 days).
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Acute Retroviral Syndrome Severity Score
For the majority (70%) of included individuals, ARSSS-values were between 1 and
3 points, with a mean of 2.89 (range 0 to 10; Fig. 1). 52 patients with PHI (18%)
were treated as inpatients. 41 patients (14%) presented with severe neurological
symptoms (e.g., encephalitis, aseptic meningitis, facial nerve paresis); of those, 18
(35%) required hospitalisation. Fever was the most common clinical sign of ARS
in 240 of 257 patients (93%), followed by malaise in 167 (65%), pharyngitis in 136
(53%), skin rash in 123 (48%), lymphadenopathy in 121 (47%) and diarrhoea in
91 (35%). Elevated liver enzymes and thrombocytopenia were present in 61% and
35%, respectively.
Table 3. Baseline characteristics of 290 patients with primary HIV-1 infection.
Total patients Female Acute infection Recent infection
n % or range n % n % n %
Number of patients 290 100 19 7 242 83 48 17
Male 271 93 228 93 44 96
Female 19 7 16 7 2 4
Age (years) 36 18–70 34 19–55 36 18–70 35 19–63
HIV-1 Subtype Ba 220 76 5 26 179 77 37 80
Transmission mode
MSM 225 78 185 76 40 87
Heterosexual 59 20 19 100 51 22 6 13
IVDU 4 1 5 2
Others b 2 1 1 1 3 7
STIsc 49 17 1 5 36 15 12 26
Initial presentation
General practitioner 141 49 7 37 119 49 22 45
Hospital 69 24 8 42 58 23 11 28
Outpatient unit 42 14 2 11 41 18 1 2
Othersd 38 12 22 11 24 10 14 25
TDR 23 8 0 0 21 9 2 4
Fiebig stagese
I/II 3 1.0 3 1.0
II–III 48 17 3 16 48 20
IV–VI 218 75 14 74 174 72 42 92
Median baseline viral load log10 RNA 6.6 1.8–8 6.1 3.6–7 6.7 1.8–8 5.3 2.4–6.4
Median baseline CD4 cell count cells/ml 429 75–1255 443 133–840 412 75–1240 516 164–1255
Abbreviations: MSM: men who have sex with men; IVDU, intravenous drug users; STIs, sexually transmitted infections; HIV-1, human immunodeficiency
virus type 1; TDR, transmitted drug resistance.
aOther subtypes: CRF01_AE, C, A, F1, G, CRF02_AG, CRF14_BG, A1D, CR 12_BF, D
bOne case from a needle stick.
cConcomitant STIs: syphilis and/or chlamydia and/or gonorrhoea and/or genital herpes
dNon infectious disease specialist or other institutions (e.g. dermatologist, gynaecologist, blood donation center etc.).
eIn 21 patients a Fiebig stage could not be assigned due to missing p24-antigen values.
doi:10.1371/journal.pone.0114111.t003
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Association of ARSSS with baseline CD4+ cell count, baseline
viral load, and viral setpoint
Baseline viral load
In univariable analysis, HIV-RNA levels at baseline increased significantly with
increasing ARSSS (p,0.001, n5290). This analysis may be confounded by the
time of viral load measurement, because during PHI the HIV-plasma RNA values
are highly dynamic and change rapidly [40]. Thus, in the multivariable analysis we
corrected for this potential bias by including the EDI. After correction, the
association between ARSSS and baseline viral load remained highly significant
(p,0.001).
Baseline CD4+ cell count
In univariable analysis, an increasing ARSSS was inversely correlated with baseline
CD4+ cell count (p50.03, n5289). The same result was found in multivariable
analysis corrected for time (p50.03; n5289). In the above models, there was a
significant association between ARSSS and CD4+ cell count and viral load,
respectively: In multivariable models, an increase of one scoring point
corresponded to a 0.10 log increase in baseline VL and a CD4+cell count decline of
12 cells/ml, respectively (Fig. 2).
Setpoint viral load in patients without eART
Similar results were found for patients without eART (n564). In this subset,
individual sVL after 90 days of infection were calculated, showing that higher
ARSSS were significantly associated with higher sVL (p50.029).
Fig. 1. Distribution of scoring points matched to the study subjects. The ARSSS consists of six variables
(see Table 1) with an individual count of scoring points for each variable. The mean ARSSS in 290 study
subjects was 2.89 points, the majority of them had an ARSSS between 1–3 points.
doi:10.1371/journal.pone.0114111.g001
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Setpoint viral load in patients after controlled treatment interruption of eART
In contrast to untreated patients, no significant correlation between ARSSS and
the level of the sVL was found after controlled treatment interruption (p50.28,
n540).
ARSSS and time to treatment and HIV-1 RNA suppression
To test the hypothesis that individuals with a high ARSSS were treated faster, we
investigated whether there was a correlation between an ARSSS above the median
value and the time to treatment (i.e. time period between the first positive test and
the start of treatment). Indeed, these individuals were treated significantly faster
than individuals with an ARSSS below the median value (p50.004 in a Cox-
proportional hazard model with start of ART as an outcome). The impact of
having an ARSS above the median value remained significant when we considered
whether patients received treatment within a given time-window (using logistic
regression with ‘‘receiving treatment within 7 days after positive HIV test’’ as
outcome: p50.05, OR [95%CI] 51.8 [1.0, 3.3]; within 14 days: p,0.001, OR
[95%CI] 52.5 [1.5, 4.0]; within 28 days: p50.01, OR [95%CI] 52.2 [1.2, 4.0];
within 60 days: p50.001, OR [95%CI]55.3 [1.8, 16]; or within 84 days: p50.002,
OR [95%CI]54.8 [1.6, 14.3]). After adjusting for CD4+ cell values at baseline, the
association between ARSSS and time to treatment persists and the magnitude of
the association is only slightly weaker: for 7 days 1.6 [0.9, 3.0]; for 14 days 2.2 [1.3,
3.6]; for 28 days 2.0 [1.1,3.6]; for 60 days 4.7 [1.6,13.9]; and for 84 days 4.2 [1.4,
12.5]. After ZPHI enrollment, 171 of all 290 patients (59%) started an eART
within one day. However, patients with an ARSSS above the median score were
significantly more likely to start an eART within one day than individuals with an
ARSSS below the median value (p50.04). Within 7 days, 222 of the 290 (77%)
Fig. 2. Relationship between the ARSSS and the log HIV-1 RNA (copies/ml plasma) and the CD4+ cell
count after an estimated duration of infection of 90 days. There is an inverse correlation between CD4+
cell count (green line) and the HIV-1 viral load (blue line) and the level of ARSSS. The grey area indicates the
95% confidence interval of the viral load and the green dotted line that of the CD4+ cell count, respectively.
doi:10.1371/journal.pone.0114111.g002
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enrolled study subjects had started eART. No correlation was found between the
ARSSS and time to virus suppression.
Genetics and immunogenetics of ARSSS
Genome-wide genotyping was performed for 250 patients. After SNP quality
control and exclusion of population outliers, 652,904 SNPs were available for
association testing, from 196 patients of European ancestry. After correction for
multiple testing, no association between ARSSS and human SNPs or HLA class I
types was found. In particular, the SNPs tagging HLA-B*5701 (rs2395029) and
HLA-C expression levels (rs9264942), which are the strongest genetic predictors
of HIV-1 control [41], did not discriminate between patients with high or low
ARSSS.
Discussion
The most relevant finding of this study is that the newly developed ARSSS, a risk
stratification score based on simple and easily obtainable clinical and laboratory
parameters, is predictive of the two major, well studied, and clinically relevant
surrogate markers associated with HIV-1 disease progression. In particular, a
significant correlation was found between the ARSSS and the baseline CD4+ cell
count, the baseline viral load, and the setpoint viral load in untreated patients
with a primary HIV-1 infection.
Although a vast number of potential surrogate markers for HIV-1 disease
progression have been studied [42–44] - almost exclusively in chronically infected
patients - to date the two most important parameters in clinical practice remain
CD4+ cell count and viral load [13]. These two parameters have been validated in
very large datasets in regard to AIDS defining, non-AIDS defining clinical
endpoints and in regard to mortality [13, 45, 46]. Contrary to chronic HIV-
infection, in PHI the value of the surrogate markers CD4+ cell count and viral load
is less studied and validated due to inherent difficulties in diagnosing and
recruiting patients with PHI in large numbers and to the considerable variation of
immunological and virological parameters during PHI [40]. However, increasing
evidence shows that both a low initial CD4 cell count and a high HIV-RNA level
are predictive for rapid progression of untreated primary HIV infection [2, 4, 47].
A recent report from Lodi et al. showed that a CD4+ cell count ,350 cell/ml
within six months of seroconversion was associated with a significant increased
risk for AIDS and death in patients with PHI in the preART era [11]. Contrary to
our work, the baseline viral load was not included as predictor in this analysis.
Apart from CD4 cell count and baseline viral load, the level of sVL has been
repeatedly associated with clinical outcome [13, 14, 48], and is a key marker for
later viral control in PHI [49]. The ARSSS predicts these surrogate markers. It
could help clinicians identify, at a very early stage, patients with PHI at highest
risk of clinical disease progression and opt for an eART. Of note, 70% of the
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patients in our study had an ARSSS of 1–3, reflecting mild disease; thus, these
patients might not need immediate treatment in a resource limited setting, where
drug use may have to be triaged.
The potential usefulness of a clinical score to determine the course and
prognosis of HIV-1 diseases at the time point of seroconversion was previously
demonstrated by other groups [11, 12]: Vanhems at al. reported a significantly
increased hazard ratio for CDC category B for PHI patients with at least three
symptoms and for category C and death for those with at least five symptoms at
the time of acute infection. Lodi et al demonstrated that a clinical severe illness
(i.e., bronchitis, pneumonia, oral candidiasis, thrombocytopenia, viral meningitis/
encephalitis) at seroconversion was significantly associated with an increased risk
of AIDS and death. However, both studies included data from an era when ART
was not yet available or eART was not generally recommended. Since withholding
cART has been unethical in our study period, we focused on assessing our ARSSS
with regards to predict the best studied surrogate markers for HIV-1 disease
progression: CD4+ cell count and viral load.
One could argue that the composition of our a priori defined score is arbitrary
and a predictive model is needed. However, there is evidence that useful
algorithms can be developed without prior statistical evaluation of individual
parameters and formulas. An educated guess based on experience of investigators
and knowledge of the literature for selection of variables seem often superior,
because they are not affected by accidents of sampling [50, 51]. A classic
application of this approach is the Apgar test which is still used in clinical practice
[52]. The practicability of ARSSS in clinical routine is given by its simple
composition and lack of expensive or time-consuming laboratory variables.
An interesting finding which supports the clinical value of the ARSSS in
selecting patients for early treatment is that in contrast to the sVL in treatment-
nai¨ve patients, no correlation was found with sVL of patients having undergone
eART with subsequent treatment interruption. It has been clearly shown in several
studies that eART during PHI leads to a transient reduction of the viral setpoint
by approximately a factor of 10 when compared to deferred therapy [2, 3] and the
VISCONTI study even found some individuals who controlled HIV-RNA
spontaneously after interrupting long term eART [53]. The loss of correlation
with the ARSSS suggests that eART has a strong and, to a certain extent,
sustainable effect and can overrule the negative association of ARSSS with baseline
CD4+ cell count, baseline VL and sVL that was observed in untreated patients.
However, this absence of a signal could also be due to the limited power (only 40
patients with structured treatment interruption).
An additional value of the ARSSS lays in the fact that this score captures
patients at highest risk for HIV transmission. Several studies have demonstrated
that the risk of HIV transmission increases with higher viral load [54, 55] and the
ARSSS itself correlates with this marker. We therefore conclude that initiation of
eART in patients with a high ARSSS would also include individuals at higher risk
for HIV transmission. We acknowledge that - besides having a high viral load -
additional factors determine the infectivity of an individual (e.g., co-infections,
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sexual high-risk behavior). However, data supports that sexual transmitted
infections may increase baseline viral load in HIV infected individuals [56] and
therefore are integrated in the ARSSS to a certain extent.
Recently, it has been demonstrated that viral genetic traits can explain up to
50% of viral setpoint variation in HIV-1 infected individuals [57]. On the other
hand, host genome-wide association studies showed that variation in the HLA-B
and HLA-C genes explain up to 20% of variation in viral control, with little or no
impact of human genetic variants located elsewhere in the genome [41]. The vast
majority of all these studies, however, were carried out in chronically infected
patients. To date, neither viral nor host genetic factors are routinely used in
patient management, other than drug resistance testing and HLA testing for
abacavir hypersensitivity [58]. In our human genome analysis, no correlation
between ARSSS and HLA-B or C variation was found. This is not surprising, given
the small sample size and the relatively modest ability of HLA to predict disease
progression. It is conceivable that ARSSS integrates virus and host factors alike
and thus may be a simple clinical surrogate for the multifactorial nature of HIV-1
disease progression and useful to estimate an individual’s vulnerability for severe
disease of a patient with a PHI. Thus the ARSSS could serve as a further puzzle
piece to guide the clinician in the decision to start eART and to convince patients
from the potential benefit of eART.
Our study has strengths and limitations: Strengths: (i) Patients were seen in one
center by a stable study-team and laboratory values were measured in a central
laboratory; thus, variability of parameters analyzed could be minimized. The study
protocol has been unchanged since 2002. (ii) The study population was
homogeneous (Table 2). (iii) All but four patients were mono-infected with R5
tropic viruses as previously published [15]. Limitations: (i) We could only
evaluate the ARSSS in the context of the two major surrogate markers for HIV
disease progression, but could not assess its impact on clinical endpoints. (ii) A
potential bias might be that symptomatic patients presented earlier in general, and
baseline CD4+ cell count and VL might have been determined earlier during PHI
when CD4+ cell depletion and VL reached high levels. To circumvent this
potential bias, we corrected VL and CD4+ cell counts according to the EDI and the
significant correlation still remained. (iii) Reporting of clinical symptoms is
inherently imprecise, but this problem is reduced by combining several predictors
in the ARSSS. (iv) We chose an a priori approach to build our score based on
variables selected according to knowledge on the literature and our own
experience and did not use a statistical model evaluating individual parameters
before building the final score. Potentially, important variables could be missed. It
cannot be ruled out that the later strategy would also perform well or even better.
However, the selection of variables based on a statistical approach is more prone
to selection bias inherent to the data, which is not the case in an a priori approach
because selection of the parameters is independent on the dataset that is analyzed
using the score. Using both approaches and selecting the better performing score
would not be appropriate because they could influence each other. In aggregate,
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the fact that our a priori built score is predictive of key surrogate markers for
HIV-1 progression supports the validity of our approach.
In conclusion, the ARSSS predicts the key surrogate markers for HIV-1 disease
progression at a very early stage and thus could be used to identify patients with
PHI at highest risk of clinical disease progression and may also serve as a research
tool. It should be verified in an independent prospective cohort of PHI patients.
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